In what is seen as a response to criticism that the agency lacks teeth in monitoring drugs once they are approved for marketing, the US Food and Drug Administration on Saturday released a report from its Center for Drug Evaluation and Research (CDER) aimed at strengthening and modernizing post-market drug safety oversight.
The report, titled Advances in FDA’s Safety Program for Marketed Drugs, describes new scientific tools and enhanced capabilities that give the same priority to post-market drug safety monitoring as to premarket drug review.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze